Thank you, Madam Chair.
Thank you to all of the witnesses. Thank you for your volunteerism, your expertise, passion and the commitment that you have to make sure that you provide the best advice to the government to keep us safe.
I'm going to split my time between Madam Langley and Mr. Lievonen. Let me start with Mr. Lievonen.
Can you, based on your experience, give us an understanding of, from a manufacturing process as well as a biomanufacturing set-up, the difference between the mRNA and the traditional vaccine, and whether any of our domestic candidates were suitable to be able to ramp up an mRNA model in a very short time?